The immunohistochemistry test detects the folate receptor 1 protein, which is over-expressed in most ovarian cancers.

CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to announce, with support from the Government of Ontario through ...

Roche has secured CE mark approval for its immunohistochemistry (IHC) companion diagnostic test, VENTANA FOLR1 (FOLR1-2.1) ...

Roche (RHHBY) announced that it has received CE Mark for its Ventana FOLR1 RxDx Assay. This is the first immunohistochemistry, or IHC, ...

Discover what it takes to become a fleet champion through the real-world achievements of nominated and award-winning industry ...

Collaboration will leverage Flare Therapeutics' proteomic and mass spectrometry platform and expertise, powered by its proprietary library of electrophilic compounds ...

The European market for life science tools and reagents and COVID-19 diagnostics products was valued at $14.7 billion in 2023. The market is expected to grow from $13.0 billion in 2024 to $15.4 ...

Alongside opening the new offices, Roche Diagnostics capabilities in China have been further recognised as it has been ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CLDN18.2 is an emerging biomarker in gastric and GEJ cancers and helps predict the likelihood of response to targeted therapy.As the leader in companion diagnostics, Roche continues to build on ...

Presented at the Clinical Trials in Alzheimer’s Disease congress, being held in Madrid, Spain, Roche’s diagnostics unit showed that a negative result from one test—its Elecsys amyloid plasma ...